Stratasys ( SSYS - Free Report) recently enhanced its dental solution portfolio with the launch of Origin One Dental 3D printer, which will provide comprehensive additive manufacturing solutions to the dental industry. The newly launched printer is powered by P3 Programmable PhotoPolymerization print technology that delivers industry leading accuracy and part-to-part consistency.
The new printer enables high throughput at a lower cost per part compared to other competing technologies. It comes with an open material infrastructure, which supports a variety of applications.
It is worth mentioning that it is the second 3D printer launch related to the December 2020 buyout of San Francisco-based 3D printing start-up, Origin. The first 3D printer introduced as a result of the buyout was a compact multi-material dental 3D printer called J5 DentaJet in March 2021.
Needless to say, the integration of Origin’s software-centric additive manufacturing solutions has provided Stratasys a competitive edge in the 3D-printed mass production parts market.
The newly introduced Origin One Dental is ideal for small batch printing of a single material requiring short print time and is designed for flow production. Meanwhile, J5 DentaJet is based on PolyJet technology and is ideal for large batch printing, especially when printing mixed trays of parts overnight or unattended. However, both the printers accelerate additive manufacturing solutions for the dental customers, while streamlining their production processes.
Minnesota-based Stratasys has been gaining from growing demand for 3D printed materials. The launch of several other innovative products this year positions it well in the long haul. Recently, it launched Digital Anatomy Creator, which is a new software module designed for Digital Anatomy 3D Printers to enhance personalized healthcare through anatomic modeling solutions.
In September, it launched a new cybersecurity solution for additive manufacturing named ProtectAM. In June, it unveiled J5 MediJet, a compact medical 3D printer that integrates multiple applications into one system and thus enables the creation of intricate 3D anatomical models. The new printer runs 30% faster than other 3D printers.
Stratasys, Ltd. price-consensus-chart | Stratasys, Ltd. Quote
Stratasys currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the broader technology sector are Advanced Micro Devices ( AMD - Free Report) , Qualcomm ( QCOM - Free Report) and CDW Corporation ( CDW - Free Report) , each carrying a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here .
The Zacks Consensus Estimate for Advanced Micro Devices’ fourth-quarter 2021 earnings has been revised upward by 7 cents to 75 cents per share over the past 60 days. For 2021, earnings estimates have moved north by 1 cent to $2.64 per share in the last 60 days.
Advanced Micro Devices’ earnings beat the Zacks Consensus Estimate in each of the preceding four quarters, the average surprise being 14%. Shares of AMD have rallied 58.5% in the YTD period.
The consensus mark for Qualcomm’s first-quarter fiscal 2022 earnings has been raised to $3.01 per share from $3 in the past 30 days. For fiscal 2022, earnings estimates have been revised upward by 1.5% to $10.49 per share in the past 30 days.
Qualcomm’s earnings beat the Zacks Consensus Estimate in each of the trailing four quarters, the average surprise being 11.2%. Shares of QCOM have gained 20.6% YTD.
CDW’s consensus estimate for fourth-quarter fiscal 2021 earnings has been raised to $1.87 per share from $1.83 in the past 60 days. For fiscal 2021, earnings estimates have moved north by 0.1% to $7.81 per share over the past 30 days.
CDW’s earnings beat the Zacks Consensus Estimate in each of the trailing four quarters, the average surprise being 12.2%. Shares of CDW have appreciated 50.4% YTD.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $2.4 trillion by 2028 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Recommendations from previous editions of this report have produced gains of +205%, +258% and +477%. The stocks in this report could perform even better.
See these 7 breakthrough stocks now